MAPS – Chacruna

Back to the Roots: Psychedelic Science Rebuilds After MDMA Denial

Despite a smaller audience, the Denver (USA) event reaffirms the importance of psychotherapy in MDMA...

At Psychedelic Science 2025, Rick Doblin acknowledged setbacks in MDMA therapy approval but remained optimistic....

Recent advisory groups ICER and AdComm have recommended against FDA approval of MDMA for medical...

Geoff Bathje, initially supportive of Psymposia’s critiques within the psychedelic field, has grown skeptical of...

On June 4, an FDA advisory committee overwhelmingly rejected MDMA-assisted therapy for PTSD, citing inadequate...

Four Chacruna Institute members sit down to address eight frequently asked questions about the globalization...

In this article, Marcelo Leite outlines the major developments in psychedelic science and markets going...

Psychedelic Science 2023 brought together 12,000 registrants in Denver, Colorado, four times as many people...

Berra Yazar-Klosinski, Chief Science Officer at the MAPS Public Benefit Corporation, reflects on her journey...